Discover a clinical trial that was conducted to evaluate the efficacy and safety of autologous HBV vaccine-pulsed dendritic cells and their induced T cells.

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study ...

Researchers update clinical practice guidelines for how to prevent and monitor hepatitis B virus reactivation.

Breakthrough therapy designation recognises the potential of brelovitug to transform the lives of people living with CHD. We look forward to initiating a global pivotal trial a ...

Also referred to as BJT-778, brelovitug targets the hepatitis B virus’ surface antigen. The antibody neutralises and eliminates hepatitis B and D virions, as well as depleting HBsAg-containing ...

Brelovitug is designed to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing subviral particles, which makes brelovitug a potentially safe and highly efficacious ...

Peripheral blood T lymphocyte subsets were evaluated using flow cytometry at baseline, and at 12, 24, 48, and 72 weeks in both groups. At 72 weeks, IHCs in the treatment group were categorized into an ...

At 72 weeks, IHCs in the treatment group were categorized into an HBsAg clearance group and an HBsAg persistence group. Differences in T lymphocyte subsets among these groups were compared ...

All patients achieved hepatitis B surface antigen (HBsAg) clearance post-treatment. Result: The study enrolled 176 patients with chronic hepatitis B, with the median IFN treatment course of 35.23 ± 25 ...